FB-718A1 is under clinical development by Frontbio and currently in Phase I for Dermatitis (Eczema). According to GlobalData, Phase I drugs for Dermatitis (Eczema) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-718A1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FB-718A1 is under development for the treatment of eczema (dermatitis). The drug candidate is administered through oral route.
For a complete picture of FB-718A1’s drug-specific PTSR and LoA scores, buy the report here.